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A study of the efficacy, toxicity and pharmacokinetics
of lidocaine was performed to determine 1) the maximal
number of bolus injections that can be given every 5
minutes to suppress complex ventricular arrhythmias in
apparently refractory patients, 2) the influence of left
ventricular failure on the time course of lidocaineplasma
concentrations, and 3) the relation of plasma drug con-
centration during bolus loading and observed effects.
Twenty-one patients participated in this study (15 with
acute myocardial infarction and 6 with prolonged coro-
nary insufficiency). Nine patients had severe left ven-
tricular failure (pulmonary edema or shock, or both)
and two had moderate failure. All patients received an
initial 75 mg bolus dose (all doses were infused at 50
mg/min) followed at 5 minute intervals by 50 mg sup-
plementary bolus doses until complex arrhythmias were
abolished or signs of toxicity were observed. Nineteen
of 21 patients who failed to respond (abolition of all
complexarrhythmias and reduction oftotal ectopicbeats
Previous studies from our laboratories (1,2) demonstrated
that patients with acute myocardial infarction experiencing
recurrent complex ventricular arrhythmias during the first
hours of the attack can be treated safely and effectively with
a series of bolus injections of lidocaine. It was shown that
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to <5/min) to the maximal standard loading dose (225
mg in a 16 minute period) responded favorably to a total
loading dose of 275 to 375 mg. Furthermore, toxicity
was confined to six episodes of mild severity (numbness
of lips or tongue, mild sleepiness) and two episodes of
moderate severity (agitation, somnolence, nausea). After
the first bolus, it was observed that patients with mod-
erate-severe left ventricular failure exhibited higher
plasma concentrations than did patients without left ven-
tricular failure. However, this difference was not sus-
tained when the loading doses exceeded 175 mg.
The data suggest that a total loading dose of 375 mg
may be given if necessary over 31 minutes to patients
refractory to conventional doses, including patients with
severe left ventricular failure, and that many "lidocaine
resistant" patients have a quantitative, not qualitative,
difference in the sensitivity of their arrhythmia to this
drug.
a maximum of four bolus (doses) of lidocaine totaling 225
mg over 16 minutes could be safely administered. Utilizing
this method of treatment for patients who developed com-
plex ventricular arrhythmias, 80% of the patients exhibited
a satisfactory antiarrhythmic response after the infarction
with a total incidence of primary ventricular fibrillation of
less than 1%(1,2). When the full 225 mg dose was given,
the observed lidocaine serum concentrations were well within
the usual therapeutic range and less than 5% of the patients
exhibited any signs of central nervous system toxicity. The
low serum concentrations observed in our study and by other
investigators (3) suggest that some patients deemed "re-
fractory to lidocaine treatment" were actually "pharma-
cokinetic failures;" that is, subjects did not exhibit dose
limiting toxicity and did not attain concentrations near the
0735-1097/83/$3 00
lACC Vol. 2. No 4
October 1983.764- 9
WYMAN ET AL
LIDOCAINE BOLUS LOADING IN VENTRICULAR FAILURE
765
top of the usually accepted therapeutic range while being
treated with supposed maximal therapy (4,5). Thus, it seemed
desirable to determine if more aggressive bolus loading with
lidocaine could be adequately tolerated by patients who did
not respond to the 225 mg dose and if a significant im-
provement in the fraction of patients exhibiting arrhythmia
control could be achieved.
In addition , there has been no systematic study of lido-
caine bolus loading in patient s with an acute myocardial
infarction and severe pump failure . Furthermore, the pa-
tients who volunteered for the serum level monitoring com-
ponent of our original study received their " study doses "
of lidocaine several days after their acute myocardial in-
farction (2). Subsequent investigations established that serum
concentrations of alpha.vacid glycoprotein, the acute phase
reactant that controls the free concentration of lidocaine in
serum (6), are substantially (approximately 75%) increased
in the time period 2 to 10 days after acute myocardial in-
farction (7,8). Because elevated concentrations of this pro-
tein can influence several aspects of lidocaine pharmacok-
inetics, it was necessary to repeat the bolus loading study
in patients at the time of their amval at the hospital. Finally,
most lidocaine pharmacokinetic studies performed before
1980 (9, 10) relied on the collection of samples into evac-
uated blood tubes containing the chemical tris (butoxyethyl)
phosphate which displaces lidocaine (and many other basic
drug s) from binding sites on sigma-acid glycoprotein. This
displacement result s in a two-fold increase in the free con-
centration of lidocaine and about a 25% decrease of lido-
caine serum or plasma concentration secondary to increased
partitioning of the free drug into red blood cells (9). Because
of these recent observations and the lack of guidelines for
the administration of loading doses of lidocaine to patients
with severe pump failure who are refractory to low dose
treatment, it seemed appropriate to execute a comprehensive
study of lidocaine serum levels and pharmacology in patients
with acute ischemic heart disease who failed to respond to
conventional doses of this drug.
Methods
Patients. Twenty-one patients whose mean age was 62
years (range 50 to 83), admitted to the coronary care unit
of the San Pedro Peninsula Hospital , were studied. Twelve
were male and nine female . Patient s were selected for study
if they were refractory to our usual maximal loading dose
of 225 mg of lidocaine given over a period of 16 minutes ,
and special attention was given to the patient with a sub-
stantial degree of left ventricular failure. The diagno sis of
acute myocardi al infarction was confirmed in 15 patient s
and 6 patient s experienced prolonged attack s of coronary
insufficiency. All patients had either a history of coronary
heart disease or had suffered a myocardial infarction at the
time of the study. Three of the patients had previously
undergone saphenous vein coronary bypass surgery; 17 had
a previous myocardial infarction. Two patients had electro-
cardiographic evidence of sinus node dysfunction before the
infusion of lidocaine.
Using a previously reported rating scheme f or left ven-
tricular performance (2J. at the time of lidocaine treatment
nine patients were in pulmonary edema or shock or both
(class 4), two were in moderate congestive failure (class 3)
and one had class 2 failure (basilar rales and a third heart
sound without X-ray film evidence of congestion). The nine
remaining subjects had only a third heart sound or no evi-
dence of pump failure. The mean time from onset of symp-
toms to hospitalization was 58 minutes (range 10 to 240) .
Electrolytes were normal in 17 of 21 subjects, with the
remaining individuals exhibiting mild hypokalema (3.5, 3.7,
3.7 and 3.7 mEq/liter respectively, normal range 3.8 to 5.1)
Three patients had abnormal serum glutamic pyruvic trans-
aminase levels (41, 47 and 121 unit/rnl; normal range 22 to
37) and two had significantly elevated serum creatinine ki-
nase values (2.2 and 5.7 mg/dL; normal range 0.5 to 1.5).
Serum albumin, globulin and alkaline phosphatase levels
were normal in all patients.
Lidocaine dosing schedules. Each patient received an
initial bolus dose of 75 mg (all doses were infused at a rate
of 50 mg/min) which was followed at 5 minute intervals by
supplementary doses of 50 mg each . The refractory patients ,
who are the subject of this report , received a loading dose
of 225 to 375 mg of lidocaine hydrochloride. The complex
ventricular arrhythmias that they exhibited included paired ,
multifocal or R on T ventricular beat s and ventricular tachy-
cardia. Frequent ventricular ectopi c beats was defined as
more than 5/min.
Toxicologic/pharmacologic evaluation. Observations
performed to evaluate the toxicologic consequences of this
loading scheme included brachial artery pressure, respira-
tory rate, electrocardiographic response and central nervous
system symptoms. All assessments of lidocaine toxicity were
made by a coronary care unit nurse at the time the reaction
occurred. Lidocaine toxic reactions are listed in Table I.
Effectiveness was jud ged by constant monitoring of the
electrocardiographic signal with documentation of all ar-
rhythmias during the study period . The reduction of ectopic
ventricular beats to fewer than 5/minute and complete
suppression of complex ventricular arrhythmias during each
4 minute observation period between bolus doses was used
as the measure of effectiveness. Once effectiveness was
demonstrated , no further boluses were given and the study
was completed for that patient. These patients were then
maintained on a constant rate lidocaine infusion consistent
with our previously reported guide lines (2,5). The study
was also terminated if symptoms of toxicity continued be-
yond the 4 minute observation period.
Blood sampling and analytical method. Blood sam-
ples were drawn into glass syringes 3 minutes after the
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Table 1. Lidocaine Toxic Reactions
Class I
Numbness and tingling of tongue, lips or hands
Dizziness
Slurred speech
Mild sleepiness
Class 2
Confusion
Visual disturbances
Agitation
Somnolence
Nausea, vomiting
Class 3
Convulsions
Unresponsiveness
Cardiac conduction abnormalties
Class 4
Respiratory arrest
Cardiac arrest
initiation of each bolus dose. The plasma was transferred
into glass centrifuge tubes with Teflon-lined caps and stored
frozen until time of analysis. Lidocaine plasma concentra-
tions were determined using a modification of the method
of Tucker (11). Plasma concentrations of pharmacologically
active metabolites (monoethylglycinexylidide and glycine-
xylidide) were not measured because significant accumu-
lation of these compounds was extremely unlikely (5,12)
during the 35 minute study period. The standard quality
control procedure required the analyst to assay three coded
unknown plasma samples each day that the patient samples
were evaluated. If the mean absolute error exceeded 10%,
the analytical resultsof the day wererejectedandall samples
were reassayed with three new coded unknowns .
Analysis of data. A comparison of the two study pop-
ulations, moderate-severe left ventricularfailure (class 3-4)
and absent-mild pump failure (class 0-1), was performed
using a two-tailed Student's t test for unpaired data.
Results
Plasma lidocaine concentration. The mean plasma
concentration of lidocaineobserved 3 minutes after the ini-
tiation of each bolus dose in patients with and without
congestive heart failure is presented in Table 2. Lidocaine
plasma concentrations were substantially higher in patients
with heart failure. However, the relative magnitude of the
difference between failure and nonfailure groups decreased
as the number of boluses increased. After the first dose,
patients without heart failure exhibited a plasma concentra-
tion 40% of that seen in patients with severe congestive
heart failure (1.3 ± 0.69 versus 2.72 ± 0.80 J,Lg/ml; mean
± standard deviation; t == 3.01 probability [p] < 0.025).
After the sixth dose (cumulative bolus dose of 325 mg), the
concentration in the nonfailure group was 70% of that seen
in patients with failure (4.27 ± 3.14 versus 6.10 ± 2.58
J,Lg/ ml; t== 1.03, not significant). This trend was apparent
after each of the seven bolus doses (Table 2).
The magnitude ofthe intersubject variability in lidocaine
concentrations in patients with and without severe conges-
tive heart failure is shown in Figures I and 2. The plasma
levels presented are from the four patients who exhibited
the highest and lowest plasma concentrations.
Toxic reactions. Six patients exhibited mild toxic re-
actions (class I) and two exhibitedmoderate reactions(class
2). The mean lidocaine plasmaconcentration in the patients
with class I reactions was 5.44 J,Lg/ml and the mean level
was 6.39 J,Lg/ml in the individuals with a class 2 reaction.
In 14 patients, each of whom had received six bolus doses
(that is, 325 mg), no difference in lidocaine plasma con-
centration was found between those who exhibited signs of
toxicity (5.94 ± 3.75 J,Lg/ml) and those who did not (4.97
± 1.93 J,Lg/ml) (Table 3). Furthermore, the patients with
severe heart failure did not appear to be more sensitive to
any given plasma lidocaine concentration.
Effectiveness of lidocaine. Lidocaine was judged ef-
fective in 19 of the 21 patients who received doses of 275
to 375 mg. One of the nonresponders was switched to in-
travenous procainamide after 325 mg of lidocaineas a result
of a prolonged class 2 reaction; the lidocainelevel (3 minutes
after his last bolus) was 4.27 J,Lg/ml. The second nonre-
sponder received 375 mg of lidocaine but continued to have
complex ventricular arrhythmias. Three minutes after the
seventh bolus, the plasma concentration was 5.04 J,Lg/liters .
Both patients died with shock and pulmonary edema.
Discussion
It is almost a universal practice to administer lidocaine
to patients in the period immediately after acute myocardial
infarction if they exhibit frequent ventricular ectopic beats
or complex ventricular arrhythmias, or both. Furthermore,
it is a policy in many coronary care units to administer
prophylactic lidocaine (that is, in the absenceof arrhythmia)
in an effort to prevent primary ventricular fibrillation . Most
studies (1 ,2,13) evaluating the efficacy of lidocaine suggest
that standard dosesof this drug control malignantventricular
arrhythmias in about 80% of a typical patient population.
Thus. a more efficacious dosage regimen is desirable. Fur-
thermore, the most recent standards and guidelines from the
American Heart Association and the National Academy of
Sciences-National Research Council (14) indicate that the
absence of data prevented specific recommendations for a
loading dosage schedule to be used in patients with severe
congestive heart failure or shock. Therefore, the present
study was conducted to devise a dosing schedule to rapidly
achieve therapeutic effect in patients suspected of having
had myocardial infarction with and without severe left ven-
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Table 2. Influence of Total Lidocaine Dose and Se verity of Congestiv e Heart Failure on Lid ocaine Plasma Concentration (JLg/ml)
After Multiple Bolus Injections
Severity of
Lidocaine Dose (mg)
Heart Failure 75 125 175 225 275 325 375
Class 0-1
Mean plasma 1.13 1.66 2.39 2.97 3 47 4.27 4.13
concentration ( :±: SO) (0.69) ( 1.42) ( I 27) (1.38) (233) (3. 14) ( -)
Subjects (no.) 4 5 8 8 8 4 3
Class 3-4
Mean plasma 2.72 4.62 3.43 410 5.20 6.10 533
concentration ( :±: SO) <0.80) (1.69) (2.20) (2.56) (2.45) (2.58) ( 1.42)
Subjects (no.) 4 5 9 10 9 10 4
3.01 3.00 I 21 1.20 1.26 1.03
P < 0.025 < 0.025 > () 20 > 0.20 > 0. 20 > 0.30
The principal goal of the pharmacokinetlc component of the study was to examine lidocaine plasma concentrations observed after doses in excess
of those in common use. Thus. the number of subjects from whom samples were obtained after the first two bolus doses IS small
p = probability; SO = standard deviation; t = devianon of the estimated mean from that of the population normahzed for the sample standard
error.
tricular failure who do not respond to a conventional loading
dose regimen of lidocaine.
Technica l advantages of multiple bolus methods.
Although several methods for the administration of large
quantities of lidocaine over a brief period of time have been
reported (2, 16-18), the multiple bolus technique has certain
distinct advantages over techniques such as brief constant
high rate infusion over a preordained period (that is, infusion
duration without regard to the amount of drug required to
elicit a satisfactory antiarrhythm ic response). The multiple
bolus technique may be used by the paramedic . nurse or
physician in the field, ambul ance , emergency department,
coronary care unit or on the medical floor. The techn ique
Figure 1. Lidocaine plasma concentrations in two patients without
evidence of co ngestive heart failure. Open circles are observations
from the patient who exhibited the highest conc ent rati ons after this
bolus loading schedule . Th e solid circles are the observations from
the patient who exhibited the low est concentration s.
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provide s a method of giving the smalle st amount of drug
necessary to achieve the desired antiarrhythmic effect, not
a preordained dose based on population averages of phar-
macokinetic variables (such as , initial dilution volume and
rates of distribution) and a population average of the ther-
apeutic range of lidocaine . In addition , the clinician can
carefully evaluate tbe patient for toxic effects as the med-
ication is slowly administered. Once toxic symptoms are
observed, the rate of administration can be slowed or stopped
and subsequent boluses can be given at rates less than 50
Figure 2. Lidocaine plasm a concentrations in two patients with
moderate-severe congestive heart failure . Symbols as in Figure I .
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Numbers in parentheses = degree of heart failure, classification of
tOXICreaction. Other abbreviations as in Figure 2.
Table 3. Observed Lidocaine Plasma Concentration (l-tglml) in
Patients Receiving a Total Loading Dose of 325 mg Over a 26
Minute Period: Toxicologic Significance
mg/min or the interval between boluse s increa sed , or both .
During the period of bolus loading, the duration of toxic
symptoms is almost invariably short-lived (presumably be-
cause distribution of the drug away from receptor sites in-
volved in the toxicologic effect is rapid ). The antiarrh ythmic
and antifibrillatory effect, as observed in over 1,900 pa-
tients, is prolonged, suggesting little diminution of these
crucial response variables (1,2) while the plasma concen-
trat ion is decreasing (19).
Plasma concentration. The mean plasma concentration
of lidocaine was consistently greater in those patients with
moderate (class 3) and severe (class 4) heart failure when
compared with the patients with no clinical evidence of
failure (class 0-1). This difference was statistically signif-
icant after the first two boluses and persisted as a trend
thereafter. This reflects, in part , the reduced volume of the
initial distribution space in patients with significant pump
failure (20) and is consistent with data from our previou s
report (2) that showed that in patients with class 3 failure
the initial distribution volume was reduced by half when
compared with those with class 0-1 failure . In four patients
with pulmonary edema or shock, or both , who received 375
mg of lidocaine in 31 minutes, the mean plasma level was
5.33 ILg/m!. This mean concentration is at the upper limits
of the " usual therapeutic range."
The marked individual variation of plasma concentrations
is an important finding (Figure I and 2, Tables 2 and 3).
After 325 mg of lidoca ine in patient s with no heart failure ,
the range of plasma concentration was 1.80 to 4.551Lg/ml
and in patients with class 3 and 4 failure the range was 3.31
to 11 .81Lg/ml. Although there is little overlap between these
group s, this wide range of plasma levels emphasizes the
need to judge each patient's clinic al response rather than
Mean
:!: SO
Concentration in
Patients Without
Symptoms
of Lidocaine TOXicity
2.21 (0, 0)
3. 17 (4, 0)
33 1 (4, 0)
4.55 (0, 0)
4.88 (0, 0)
5.17 (4, 0 )
6.28 (4, 0)
7.17(4,0)
8.04 (4, 0)
4.97
1.93
Concentration in
Patients With
Symptoms
of Lidocaine TOXICIty
1.80 (I , I)
4.28 (4, I)
4.92 (4, I)
6.88 (3, I)
11.82 (3, 1)
5.94
3.75
relying on the suppo sition that a certain plasma level has
been attained after a standarized dose . The control of f re-
quent and complex ventricular ectopic beats pro vides a
meaningful way to ascertain effectiveness; the presence of
mild central nervous system side effects provides an early
method of detecting toxicity.
Toxic symptoms. To adequately assess toxicity , both
the severity and duration of the symptoms must be judged .
In this study the severity of the symptoms was graded from
I (minor) to 4 (life-threatening) (Table I). Once the duration
of the side effects exceeded the designated 4 minute interval
between bolus doses , the pharmacokinetic component of the
study was stopped. There were three such patients in our
group of 21 with a mean plasma lidocaine concentration of
5.45 jLg/m!. It is to be emph asized that the time interval of
5 minutes between bolus doses is arbitrary and if patients
are identified as having toxic symptoms at the time the next
bolus is to be given , the interval between boluses should
simply be increased. Constant observation of the patient is
essential for the safe use of this aggress ive loading schedule .
It was not possible to correlate fr equency , severity or
duration of toxic symptoms with the plasma concentration
of lidocaine. Class I and 2 toxic reaction s were observed
with levels between 1.59 and 11.8 ILg/ml with a mean of
5. 65 . In the two patients with class 2 toxic symptoms the
mean level was 6.38 ILg/m!. not statistically different from
the patients with class I toxicity. A symptom of toxicity in
one of these patient s was agitation that lasted longer than
4 minutes; the pharmacokinetic component of the study was
stopped at this point. Howe ver , the patient rece ived further
bolus doses of lidocaine with a longer interval between
injections and did obtain a satisfac tory therapeutic response .
Thus, a positive therapeutic outcome to this study was at-
tained . Six patients with class I reactions exhibited symp-
toms of toxicity that lasted less than the 4 minute interval
between bolus doses . Patient s were occasionally observed
to exhibit transient class I toxicity after the first or second
bolus but not thereafter.
At no time during the study did the patients show evidence
of cardiovascular toxicity. Although two patients had evi-
dence of sinus node abnormalities before the infusion of
lidocaine, neither had evidence of further sinus node slowing
or block during the bolus injections . There was no evidence
of atrioventricular or infranodal block or intraventri cular
conduction delay, nor was there evidence of hypotension
or clinical evidence of decreased cardiac output.
Classfication of toxic symptoms by severity and duration
provides a method of increasing the staff's awareness of the
patient' s most subtle complaints. Although each patient may
not manifest symptoms from each succeeding class before
a class 3 or 4 reaction occurs, convulsions have not occurred
in our coronary care unit in the past 10 years . The underl ying
cause of the substantial intersubject variability in the plasma
concentration-toxicologic response data remains to be es-
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tablished. Available evidence suggests that differences in
the free concentration of drug at the site of action (estimated
from the concentration of free lidocaine in plasma water)
(21) and intersubject differences in receptor sensitivity play
significant roles.
Effectiveness. Effectiveness was defined as decreasing
the frequency of ventricular ectopic beats to less than 5/minute
and complete prevention of complex ventricular arrhyth-
mias. Lidocaine was judged ineffective in 2 of the 21 pa-
tients studied and they were treated with intravenous pro-
cainamide. Neither of these patients developed ventricular
fibrillation, but both ultimately died in shockand pulmonary
edema. The response rate to lidocaine in this subset of
patients characterized by the resistance of conventional doses
was 90%. Because the mean time from onset of symptoms
(chest pain) until the initiation of lidocaine treatment was
only 58 minutes and our response rate was high, the data
suggest that the" lidocaine resistance" of early ventricular
arrhythmias is a quantitative not qualitative phenomenon
(22,23).
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